Skip to Main Content

When Biogen announced the price for Aduhelm, its controversial Alzheimer’s drug, the explanation the company gave — it represented the “overall value this treatment brings to patients, caregivers and society” — came right out of Mick Kolassa’s playbook.

For many years, Kolassa was the man drug companies turned to when they wanted advice on how to price a drug.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment